HeadlinesBriefing favicon HeadlinesBriefing

Public Markets 8 Hours

×
20 articles summarized · Last updated: LATEST

Last updated: July 12, 2026, 11:30 AM ET

Geopolitical Flashpoints Escalate

The Strait of Hormuz remained open to shipping despite Iran’s declaration of closure, a maritime advisory group stated remained open. This comes amid escalating tit-for-tat attacks between the US and Tehran. Hard-line conservatives in Iran are seeking to fill leadership voids and intensify their fight against the United States. Meanwhile, President Zelensky announced a leadership shake-up in Ukraine, with the prime minister slated to step down leadership shake-up. The wars in Iran and Ukraine underscore the limits of military force in achieving political goals.

Emerging Market AI Concentration and Niche Brokerages

Investors are reallocating capital away from AI leaders in emerging markets, where three technology stocks totaling $4.4 trillion dominate returns. This concentration raises concerns about the sustainability of market performance. In contrast, some options brokers are defying the trend of automation and artificial intelligence, continuing to thrive in the equity market continuing to thrive. These brokers leverage niche expertise to maintain their edge.

US Political Landscape and Box Office Success

Tributes poured in for Senator Lindsey Graham following his death. His passing triggers a special Republican primary election in South Carolina on August 11, with the governor able to appoint a successor appoint a successor. The state’s leaders paid tribute to Graham’s wit and support for South Carolina. Separately, the film "Michael" has surpassed $1 billion at the box office, signaling a resurgence for Lionsgate, Hollywood's last independent studio.

Retail and Technology Trends

Big-box retailers like Costco and Target are adopting new strategies to enter urban markets, capitalizing on the push for affordable housing. In the automotive sector, electric vehicle batteries are reportedly lasting longer than anticipated, though reader experiences reveal continued skepticism. The application of AI in drug discovery faces Wall Street timeline challenges, with questions about whether investors should pay a premium for the technology timeline challenges.